Latest Breaking News On - Liver meeting - Page 1 : comparemela.com

HCV Treatment Disparities: What Contributes to Gaps in Health Care Access?

Significant HCV treatment disparities due to race, socioeconomic background, stigma, and more continue to affect access to proper HCV care.

Elafibranor has 'significant, sustained treatment benefit' in PBC through 78 weeks

Elafibranor sustained biochemical response through week 78 in patients with primary biliary cholangitis and has a “potential beneficial effect” on itch-related quality of life, according to late-breaking data presented at EASL Congress.“There is a major unmet need for a primary biliary cholangitis (PBC) treatment that effectively targets the biochemical indicators of disease

Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update

End-of-treatment data from two Phase 2a combination clinical trials with imdusiran to be presented at the EASL Congress in June 2024 Preliminary data from the single-dose portion of the AB-101-001.

Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results

The latest research, treatments for biliary diseases presented at The Liver Meeting